LPL Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-13,375
| Closed | -$40.7K | – | 5563 |
|
|
2024
Q4 | $40.7K | Sell |
13,375
-29,530
| -69% | -$129K | ﹤0.01% | 5126 |
|
|
2024
Q3 | $223K | Sell |
42,905
-7,220
| -14% | -$35.9K | ﹤0.01% | 4657 |
|
|
2024
Q2 | $129K | Buy |
50,125
+2,132
| +4% | +$7.28K | ﹤0.01% | 4685 |
|
|
2024
Q1 | $236K | Buy |
47,993
+8,796
| +22% | +$52.1K | ﹤0.01% | 4378 |
|
|
2023
Q4 | $345K | Buy |
39,197
+16,403
| +72% | +$134K | ﹤0.01% | 3986 |
|
|
2023
Q3 | $261K | Sell |
22,794
-978
| -4% | -$18.8K | ﹤0.01% | 4038 |
|
|
2023
Q2 | $602K | Buy |
23,772
+1,386
| +6% | +$43.2K | ﹤0.01% | 3272 |
|
|
2023
Q1 | $721K | Buy |
22,386
+8,363
| +60% | +$261K | ﹤0.01% | 3026 |
|
|
2022
Q4 | $259K | Sell |
14,023
-13,321
| -49% | -$305K | ﹤0.01% | 3777 |
|
|
2022
Q3 | $738K | Buy |
27,344
+14,001
| +105% | +$284K | ﹤0.01% | 2788 |
|
|
2022
Q2 | $184K | Buy |
13,343
+3,090
| +30% | +$47.6K | ﹤0.01% | 3984 |
|
|
2022
Q1 | $200K | Buy |
+10,253
| New | +$155K | ﹤0.01% | 3828 |
|
|
2021
Q4 | – | Sell |
-19,347
| Closed | -$539K | – | 4471 |
|
|
2021
Q3 | $539K | Sell |
19,347
-6,805
| -26% | -$194K | ﹤0.01% | 3152 |
|
|
2021
Q2 | $775K | Sell |
26,152
-3,342
| -11% | -$96.4K | ﹤0.01% | 2783 |
|
|
2021
Q1 | $824K | Sell |
29,494
-1,497
| -5% | -$41.4K | ﹤0.01% | 2571 |
|
|
2020
Q4 | $878K | Sell |
30,991
-9,893
| -24% | -$256K | ﹤0.01% | 2288 |
|
|
2020
Q3 | $1.03M | Buy |
40,884
+1,190
| +3% | +$31.2K | ﹤0.01% | 1932 |
|
|
2020
Q2 | $969K | Buy |
+39,694
| New | +$783K | ﹤0.01% | 1845 |
|
Other funds holding RVNC
LPL Financial's RVNC Position: Q1 2025 in Review
LPL Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,375 shares — an estimated $40.7K sold.
LPL Financial first reported a position in RVNC in Q2 2020 and held it in 18 quarters. The position peaked at $1.03M in Q3 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- LPL Financial reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- LPL Financial sold 13,375 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $40.7K.
- LPL Financial first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 18 quarters.
- LPL Financial's Revance Therapeutics, Inc. position peaked at $1.03M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on LPL Financial's 13F filing for Q1 2025, filed 7 May 2025.